Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study
Background. FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess condi...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2022-07, Vol.2022, p.1-9 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Journal of oncology |
| container_volume | 2022 |
| creator | van der Sijde, Fleur van Dam, Jacob L. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Homs, Marjolein Y. V. Mathijssen, Daniëlle Besselink, Marc G. Wilmink, Johanna W. van Eijck, Casper H. J. |
| description | Background. FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess conditional survival after FOLFIRINOX. Methods. A multicenter, retrospective cohort study was conducted in four hospitals in the Netherlands. Consecutive patients with LAPC or metastatic PDAC, treated with FOLFIRINOX, were included. Results. Between 2012 and 2018, 284 patients were included: n = 136 with LAPC and n = 148 with metastatic PDAC. Objective response rates were similar in both the groups: 14.0% in LAPC and 18.2% in metastatic patients. The disease control rate was higher in LAPC patients (77.2%) compared to metastatic PDAC (51.4%, P |
| doi_str_mv | 10.1155/2022/8549487 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9283068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710569951</galeid><sourcerecordid>A710569951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-ae58a9177a353a54b59d456cd1a5eb20f8f97ed30a89d8e94d920eb49913cf813</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREthxwNYYoNUQu3xPwukaNRApEBQWyR2ljP2NK4mdrA9qfoCPDeeJqpaFqzu1fV3zz2yTlW9RfAjQpSe1bCuzwQlkgj-rDpGTPCJIBQ-f9QfVa9SuoGQESjZy-oIU0E4ZvS4-nMVrc4b6zO4sGkbfLJAewOa4I3LLnjdg8sh7tyuNM6Dqdlp31oDfpQyrroWNOMklkl2RSeBe8mC3Lq8BrPlYja_mH9f_voEpuDb0JeNQhW-CesQM7jMg7l7Xb3odJ_sm0M9qX7Ozq-ar5PF8su8mS4mLaE4T7SlQkvEucYUa0pWVBpCWWuQpnZVw050kluDoRbSCCuJkTW0KyIlwm0nED6pPu91t8NqY83oJOpebaPb6Hingnbq6Yt3a3UddkrWAkMmisD7g0AMvwebstq41Nq-196GIamaSUSoYLIu6Lt_0JswxPKh9xQUmHPyiLrWvVXOd6HcbUdRNeUIUiYlHX1_2FNtDClF2z1YRlCNMVBjDNQhBgU_3eNr542-df-n_wJWRbBq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2690837742</pqid></control><display><type>article</type><title>Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study</title><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>van der Sijde, Fleur ; van Dam, Jacob L. ; Groot Koerkamp, Bas ; Haberkorn, Brigitte C. M. ; Homs, Marjolein Y. V. ; Mathijssen, Daniëlle ; Besselink, Marc G. ; Wilmink, Johanna W. ; van Eijck, Casper H. J.</creator><contributor>Sun, Yingming ; Yingming Sun</contributor><creatorcontrib>van der Sijde, Fleur ; van Dam, Jacob L. ; Groot Koerkamp, Bas ; Haberkorn, Brigitte C. M. ; Homs, Marjolein Y. V. ; Mathijssen, Daniëlle ; Besselink, Marc G. ; Wilmink, Johanna W. ; van Eijck, Casper H. J. ; Sun, Yingming ; Yingming Sun</creatorcontrib><description>Background. FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess conditional survival after FOLFIRINOX. Methods. A multicenter, retrospective cohort study was conducted in four hospitals in the Netherlands. Consecutive patients with LAPC or metastatic PDAC, treated with FOLFIRINOX, were included. Results. Between 2012 and 2018, 284 patients were included: n = 136 with LAPC and n = 148 with metastatic PDAC. Objective response rates were similar in both the groups: 14.0% in LAPC and 18.2% in metastatic patients. The disease control rate was higher in LAPC patients (77.2%) compared to metastatic PDAC (51.4%, P<0.001). Median overall survival (OS) in LAPC patients was 12.7 months (95% CI 11.4–14.1 months). Their 2-year survival probability increased from 14% to 26% one year after the completion of FOLFIRINOX. Median OS in metastatic PDAC patients was 8.1 months (95% CI 6.5–9.6 months); 2-year survival probability increased from 10% to 29% after one year. Discussion. Our study provides real-world estimates of response rates, survival, and conditional survival in patients with advanced PDAC treated with FOLFIRINOX. These results are useful for patient counseling and clinical decision making.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/8549487</identifier><identifier>PMID: 35847365</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Analysis ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Chemotherapy ; Cohort analysis ; Decision making ; Development and progression ; Hospitals ; Medical imaging ; Medical prognosis ; Metastasis ; Neutropenia ; Oncology, Experimental ; Pancreatic cancer ; Patient outcomes ; Patients ; Probability ; Radiation ; Response rates</subject><ispartof>Journal of oncology, 2022-07, Vol.2022, p.1-9</ispartof><rights>Copyright © 2022 Fleur van der Sijde et al.</rights><rights>COPYRIGHT 2022 John Wiley & Sons, Inc.</rights><rights>Copyright © 2022 Fleur van der Sijde et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 Fleur van der Sijde et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-ae58a9177a353a54b59d456cd1a5eb20f8f97ed30a89d8e94d920eb49913cf813</citedby><cites>FETCH-LOGICAL-c453t-ae58a9177a353a54b59d456cd1a5eb20f8f97ed30a89d8e94d920eb49913cf813</cites><orcidid>0000-0003-1917-6973 ; 0000-0003-2650-9350 ; 0000-0002-9511-2157 ; 0000-0002-6947-9035 ; 0000-0002-1677-1278 ; 0000-0002-0634-4918</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283068/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283068/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>Sun, Yingming</contributor><contributor>Yingming Sun</contributor><creatorcontrib>van der Sijde, Fleur</creatorcontrib><creatorcontrib>van Dam, Jacob L.</creatorcontrib><creatorcontrib>Groot Koerkamp, Bas</creatorcontrib><creatorcontrib>Haberkorn, Brigitte C. M.</creatorcontrib><creatorcontrib>Homs, Marjolein Y. V.</creatorcontrib><creatorcontrib>Mathijssen, Daniëlle</creatorcontrib><creatorcontrib>Besselink, Marc G.</creatorcontrib><creatorcontrib>Wilmink, Johanna W.</creatorcontrib><creatorcontrib>van Eijck, Casper H. J.</creatorcontrib><title>Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study</title><title>Journal of oncology</title><description>Background. FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess conditional survival after FOLFIRINOX. Methods. A multicenter, retrospective cohort study was conducted in four hospitals in the Netherlands. Consecutive patients with LAPC or metastatic PDAC, treated with FOLFIRINOX, were included. Results. Between 2012 and 2018, 284 patients were included: n = 136 with LAPC and n = 148 with metastatic PDAC. Objective response rates were similar in both the groups: 14.0% in LAPC and 18.2% in metastatic patients. The disease control rate was higher in LAPC patients (77.2%) compared to metastatic PDAC (51.4%, P<0.001). Median overall survival (OS) in LAPC patients was 12.7 months (95% CI 11.4–14.1 months). Their 2-year survival probability increased from 14% to 26% one year after the completion of FOLFIRINOX. Median OS in metastatic PDAC patients was 8.1 months (95% CI 6.5–9.6 months); 2-year survival probability increased from 10% to 29% after one year. Discussion. Our study provides real-world estimates of response rates, survival, and conditional survival in patients with advanced PDAC treated with FOLFIRINOX. These results are useful for patient counseling and clinical decision making.</description><subject>Analysis</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cohort analysis</subject><subject>Decision making</subject><subject>Development and progression</subject><subject>Hospitals</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Neutropenia</subject><subject>Oncology, Experimental</subject><subject>Pancreatic cancer</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Probability</subject><subject>Radiation</subject><subject>Response rates</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ks1uEzEUhUcIREthxwNYYoNUQu3xPwukaNRApEBQWyR2ljP2NK4mdrA9qfoCPDeeJqpaFqzu1fV3zz2yTlW9RfAjQpSe1bCuzwQlkgj-rDpGTPCJIBQ-f9QfVa9SuoGQESjZy-oIU0E4ZvS4-nMVrc4b6zO4sGkbfLJAewOa4I3LLnjdg8sh7tyuNM6Dqdlp31oDfpQyrroWNOMklkl2RSeBe8mC3Lq8BrPlYja_mH9f_voEpuDb0JeNQhW-CesQM7jMg7l7Xb3odJ_sm0M9qX7Ozq-ar5PF8su8mS4mLaE4T7SlQkvEucYUa0pWVBpCWWuQpnZVw050kluDoRbSCCuJkTW0KyIlwm0nED6pPu91t8NqY83oJOpebaPb6Hingnbq6Yt3a3UddkrWAkMmisD7g0AMvwebstq41Nq-196GIamaSUSoYLIu6Lt_0JswxPKh9xQUmHPyiLrWvVXOd6HcbUdRNeUIUiYlHX1_2FNtDClF2z1YRlCNMVBjDNQhBgU_3eNr542-df-n_wJWRbBq</recordid><startdate>20220707</startdate><enddate>20220707</enddate><creator>van der Sijde, Fleur</creator><creator>van Dam, Jacob L.</creator><creator>Groot Koerkamp, Bas</creator><creator>Haberkorn, Brigitte C. M.</creator><creator>Homs, Marjolein Y. V.</creator><creator>Mathijssen, Daniëlle</creator><creator>Besselink, Marc G.</creator><creator>Wilmink, Johanna W.</creator><creator>van Eijck, Casper H. J.</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1917-6973</orcidid><orcidid>https://orcid.org/0000-0003-2650-9350</orcidid><orcidid>https://orcid.org/0000-0002-9511-2157</orcidid><orcidid>https://orcid.org/0000-0002-6947-9035</orcidid><orcidid>https://orcid.org/0000-0002-1677-1278</orcidid><orcidid>https://orcid.org/0000-0002-0634-4918</orcidid></search><sort><creationdate>20220707</creationdate><title>Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study</title><author>van der Sijde, Fleur ; van Dam, Jacob L. ; Groot Koerkamp, Bas ; Haberkorn, Brigitte C. M. ; Homs, Marjolein Y. V. ; Mathijssen, Daniëlle ; Besselink, Marc G. ; Wilmink, Johanna W. ; van Eijck, Casper H. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-ae58a9177a353a54b59d456cd1a5eb20f8f97ed30a89d8e94d920eb49913cf813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cohort analysis</topic><topic>Decision making</topic><topic>Development and progression</topic><topic>Hospitals</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Neutropenia</topic><topic>Oncology, Experimental</topic><topic>Pancreatic cancer</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Probability</topic><topic>Radiation</topic><topic>Response rates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Sijde, Fleur</creatorcontrib><creatorcontrib>van Dam, Jacob L.</creatorcontrib><creatorcontrib>Groot Koerkamp, Bas</creatorcontrib><creatorcontrib>Haberkorn, Brigitte C. M.</creatorcontrib><creatorcontrib>Homs, Marjolein Y. V.</creatorcontrib><creatorcontrib>Mathijssen, Daniëlle</creatorcontrib><creatorcontrib>Besselink, Marc G.</creatorcontrib><creatorcontrib>Wilmink, Johanna W.</creatorcontrib><creatorcontrib>van Eijck, Casper H. J.</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Sijde, Fleur</au><au>van Dam, Jacob L.</au><au>Groot Koerkamp, Bas</au><au>Haberkorn, Brigitte C. M.</au><au>Homs, Marjolein Y. V.</au><au>Mathijssen, Daniëlle</au><au>Besselink, Marc G.</au><au>Wilmink, Johanna W.</au><au>van Eijck, Casper H. J.</au><au>Sun, Yingming</au><au>Yingming Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study</atitle><jtitle>Journal of oncology</jtitle><date>2022-07-07</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Background. FOLFIRINOX chemotherapy is the current Dutch standard of care for locally advanced (LAPC) and metastatic pancreatic cancer (PDAC) patients with good performance status. The objective of this study was to evaluate real-world response rates and survival in advanced PDAC and to assess conditional survival after FOLFIRINOX. Methods. A multicenter, retrospective cohort study was conducted in four hospitals in the Netherlands. Consecutive patients with LAPC or metastatic PDAC, treated with FOLFIRINOX, were included. Results. Between 2012 and 2018, 284 patients were included: n = 136 with LAPC and n = 148 with metastatic PDAC. Objective response rates were similar in both the groups: 14.0% in LAPC and 18.2% in metastatic patients. The disease control rate was higher in LAPC patients (77.2%) compared to metastatic PDAC (51.4%, P<0.001). Median overall survival (OS) in LAPC patients was 12.7 months (95% CI 11.4–14.1 months). Their 2-year survival probability increased from 14% to 26% one year after the completion of FOLFIRINOX. Median OS in metastatic PDAC patients was 8.1 months (95% CI 6.5–9.6 months); 2-year survival probability increased from 10% to 29% after one year. Discussion. Our study provides real-world estimates of response rates, survival, and conditional survival in patients with advanced PDAC treated with FOLFIRINOX. These results are useful for patient counseling and clinical decision making.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>35847365</pmid><doi>10.1155/2022/8549487</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1917-6973</orcidid><orcidid>https://orcid.org/0000-0003-2650-9350</orcidid><orcidid>https://orcid.org/0000-0002-9511-2157</orcidid><orcidid>https://orcid.org/0000-0002-6947-9035</orcidid><orcidid>https://orcid.org/0000-0002-1677-1278</orcidid><orcidid>https://orcid.org/0000-0002-0634-4918</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2022-07, Vol.2022, p.1-9 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9283068 |
| source | Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Analysis Cancer Cancer patients Cancer therapies Care and treatment Chemotherapy Cohort analysis Decision making Development and progression Hospitals Medical imaging Medical prognosis Metastasis Neutropenia Oncology, Experimental Pancreatic cancer Patient outcomes Patients Probability Radiation Response rates |
| title | Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A41%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Response%20and%20Conditional%20Survival%20in%20Advanced%20Pancreatic%20Cancer%20Patients%20Treated%20with%20FOLFIRINOX:%20A%20Multicenter%20Cohort%20Study&rft.jtitle=Journal%20of%20oncology&rft.au=van%20der%20Sijde,%20Fleur&rft.date=2022-07-07&rft.volume=2022&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/8549487&rft_dat=%3Cgale_pubme%3EA710569951%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2690837742&rft_id=info:pmid/35847365&rft_galeid=A710569951&rfr_iscdi=true |